Immuno-oncology collaborations numbers keep climbing.
|
Scooped by Laurent LEVY |
Scoop.it!
No comment yet.
Sign up to comment
Research and publish the best content.
Get Started for FREE
Sign up with Facebook Sign up with Twitter
I don't have a Facebook or a Twitter account
Already have an account: Login
Therapeutic cancer vaccines
844 views | +0 today
 Your new post is loading...
Your new post is loading...
Scoop.it!
Scoop.it!
In lung cancer patients who were taking immunotherapy drugs targeting the PD-1 pathway, testing for CD8 T cell activation in their blood partially predicted whether their tumors would shrink.
Scoop.it!
The leading news and search platform for precision medicine and medical diagnostics. From biomarkers to genetic testing and molecular diagnostics, a comprehensive review of up-to-date information required by researchers and physicians.
Scoop.it!
Beacon Intelligence | Hanson Wade
Laurent LEVY's insight:
A spectacular visualization of the IO network • Currently there are 746 IO combination clinical trials (correct as of Aug 11th 2016) • These involve 47 different ICIs • 295 organizations are involved in these trials
Scoop.it!
Merck will pay $200 million upfront to Moderna, which the company will use to lead all R&D efforts through proof of concept and to build out a suburban Boston manufacturing facility. The program will focus on several types of cancer and include combinations with Merck’s Keytruda (pembrolizumab).
Scoop.it!
Using a special type of cell known as a dendritic cell that is a key regulator in the immune system, a U.S. company has created an immunotherapy treatment for lung cancer that is personalized to the patient’s specific tumor characteristics.
Scoop.it!
Emerging data is suggesting that the process of dendritic cell (DC) tolerization is an important step in tumorigenesis. Our understanding of the networks within the tumor microenvironment that functionally tolerize DC function is evolving while methods for genetically manipulating DC .
Scoop.it!
Boehringer Ingelheim Venture Fund has led a Series A investment intended to propel peptide-based cancer vaccine startup Amal Therapeutics toward clinical trials. The startup landed the investment on the strength of technology it thinks can address some of the historic failings of cancer vaccines.
Laurent LEVY's insight:
Share your insight
Scoop.it!
One year ago, in a paper in the journal Oncoimmunology, three cancer researchers wrote this: "After many years of best efforts and countless dollars, but u
Scoop.it!
PUNE, India, November 5, 2015 /PRNewswire/ -- Cancer Immunotherapy Market to Reach $9 Billion Across the World by 2022.
Scoop.it!
Celldex Therapeutics, Inc. (NASDAQ:CLDX) has contributed to medical science field in a number of ways over the last many years, but things have changed now. Reports claim that it has stopped Phase …
Scoop.it!
Scientists at the University College London (UCL) have made a major breakthrough that may further cement so-called immunotherapies' status as the most promising advance in cancer treatments in years. The researchers published their findings in the journal Science.
|
Scoop.it!
The top 15 immuno-oncology collaborations' total value of all 15 ranked collaborations is approximately $30 billion.
Scoop.it!
Though cancer vaccines have experienced disappointing clinical performance in recent years, their global market as a crucial tool in immunotherapy will grow from $2.5 billion in 2015 to $7.5 billion by 2022, a new report predicts.
Scoop.it!
Decibio offers expert Mdx market reports, analysis of Life Sciences research tools market trends, NGS market growth reports, and DME market outlook reports.
Scoop.it!
Moderna Therapeutics still hasn’t produced data in humans supporting its technology, which is meant to turn our bodies into little drugmaking factories. Bu
Scoop.it!
Deal covering tumor cell/dendritic cell technology is second licensing agreement between the companies since February
Laurent LEVY's insight:
Caladrius—which changed its name last year from NeoStem—has also refocused its clinical development efforts on CLBS03, a Phase II T regulatory cell therapy candidate for type 1 diabetes
Scoop.it!
DURHAM, N.C., March 23, 2016 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) (
Laurent LEVY's insight:
AGS-003 is an individualized immunotherapy designed to induce a memory T-cell response specific to each patient's cancer, including the unique tumor mutations (or neoantigens). It is produced using a small sample of RNA from a patient's own tumor, and dendritic cells derived from a cell collection procedure from the patient
Scoop.it!
Vx-001 is a therapeutic cancer vaccine based on proprietary antigens known as optimised cryptic tumou
Laurent LEVY's insight:
A total of 220 patients with metastatic NSCLC have now been enrolled in this Phase IIb trial across 70 European trial centres. The primary endpoint is to assess the benefit of Vx-001 versus placebo on overall survival. Final trial results are expected in the fourth quarter of 2016.
Scoop.it!
Laurent LEVY's insight:
The new indication in non-small cell lung cancer (NSCLC) is for patients with squamous cell-derived tumours who have previously been treated for the disease with chemotherapy - adding to its existing second-line use in non-squamous NSCLC and for newly-diagnosed and previously-treated melanoma
Scoop.it!
In this webcast from the 2015 CCO ACCC live meeting series on the Principles and Application of Immunotherapy for Cancer, Heather Wakelee, MD, provide
Scoop.it!
Argos Therapeutics reached an investment deal that provides up to $60 million in financing as the drug developer plows ahead on late-stage clinical trial w
|
